Heart Failure, Congestive Clinical Trial
Official title:
Anti-Arrhythmic Effects of Exercise After an Implantable Cardioverter Defibrillator (ICD)
An implantable cardioverter-defibrillator (ICD) is a small device that is surgically implanted in the chest or abdomen and uses electrical pulses or shocks to help control life-threatening, irregular heartbeats. Increasing aerobic exercise may provide health benefits to people with ICDs. This study will examine the effects of an exercise program on heart and lung function in people who have an ICD.
An ICD is a device designed to quickly detect a life-threatening, rapid heartbeat. Through a
process called defibrillation, the ICD tries to convert an abnormal heart rhythm back to
normal by delivering an electrical shock to the heart. The ICD continuously monitors
heartbeats to ensure that they are normal, and it only delivers a shock to the heart when it
senses a life-threatening rhythm. People who have experienced ventricular fibrillation,
which is a severely abnormal heart rhythm, or ventricular tachycardia, which is a rapid
heart beat that begins in the bottom chambers of the heart, are common recipients of an ICD.
Other potential ICD recipients include people who have survived a heart attack, but have
weak hearts; people with heart muscle problems; and people with reduced pumping function in
their heart. People who have ICDs may benefit from aerobic exercise to improve their
physical fitness and overall health. The purpose of this study is to evaluate the
effectiveness of an exercise program at improving heart and lung function in people who have
an ICD.
In this 6-month study, participants will be randomly assigned to either take part in the
exercise program or receive usual care. At a baseline study visit, all participants will
complete an exercise treadmill test, wear a Holter monitor to record heart activity for 24
hours, undergo blood collection, and complete questionnaires to assess quality of life,
anxiety, and depression. Participants taking part in the exercise program will receive 1
hour of exercise education over the telephone. During Weeks 1 through 8, participants will
stretch for 10 minutes and walk 1 hour daily for 5 days a week; during Weeks 9 through 24,
participants will walk 30 minutes daily for 5 days a week. Participants will wear a Polar
Heart Rate monitor to record their heart rate and a pedometer to keep track of the number of
steps walked. They will also record details of their exercise in a daily activity log.
Throughout the entire study, a study nurse will call participants on a weekly basis to check
on their progress and to help resolve any exercise-related problems. At Weeks 8 and 24, all
participants including those receiving usual care, will attend a study visit for repeat
baseline evaluations. Study researchers will review medical records to collect various
information, including the reason for needing an ICD, the type and settings of the ICD,
medication use, medical history, current health problems, lab test results, echocardiogram
images of the heart, and electrocardiogram (EKG) results.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01357850 -
A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure
|
Phase 2 | |
Recruiting |
NCT00532688 -
N-Acetylcysteine in Heart Failure With Coexistent Chronic Renal Failure
|
Phase 2/Phase 3 | |
Completed |
NCT00531661 -
CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients
|
N/A | |
Terminated |
NCT00383630 -
Bone Marrow Cell Transplantation to Improve Heart Function in Individuals With End-Stage Heart Failure
|
Phase 2 | |
Completed |
NCT00241761 -
Epidemiology of Depression and Heart Failure in Aging
|
N/A | |
Completed |
NCT00149435 -
Cardiovascular Health Study (CHS) Events Follow-up Study
|
||
Completed |
NCT00159614 -
Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment
|
Phase 2 | |
Terminated |
NCT00125437 -
Larger Dose of Spironolactone for the Treatment of Patients With Nonischemic Cardiomyopathy
|
N/A | |
Completed |
NCT00202579 -
Efficacy and Safety of Ivabradine in Severe Congestive Heart Failure
|
Phase 2 | |
Terminated |
NCT00357591 -
Randomized Trial for Patients With Chronic Heart Failure With Acute Decompensation
|
N/A | |
Completed |
NCT00094263 -
Long-Term Predictors of Morbidity in Older Age
|
N/A | |
Completed |
NCT00048425 -
Evaluation of Intravenous Levosimendan Efficacy in the Short Term Treatment of Decompensated Chronic Heart Failure.
|
Phase 3 | |
Completed |
NCT00023556 -
Genetic Architecture of Heart Disease in Rural Brazil
|
N/A | |
Completed |
NCT00530426 -
Heart Failure Registry
|
Phase 4 | |
Terminated |
NCT00190359 -
Growth Hormone and Heart Failure
|
N/A | |
Completed |
NCT00004562 -
Occluded Artery Trial (OAT)
|
Phase 3 | |
Completed |
NCT00005265 -
Natural History of Coronary Heart Disease
|
N/A | |
Completed |
NCT02772068 -
Hemodynamic Response to Exercise in HFpEF Patients After Upregulation of SERCA2a
|
Early Phase 1 | |
Completed |
NCT02925546 -
A Phase I Study to Assess the Pharmacokinetics of GSK2798745 Tablets
|
Phase 1 | |
Completed |
NCT01074307 -
A Prospective, Open-labeled, Multi-centric Trial in Subjects With Systolic Heart Failure to Evaluate Bisoprolol Treatment for the Effects on Surrogate Markers of Heart Failure in Korea
|
Phase 4 |